Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PMDA Reports Increased Inquiries On Adverse Effects Patient Relief System

This article was originally published in PharmAsia News

Executive Summary

Japan's Pharmaceutical and Medical Device Agency reported it received 17,296 inquiries related to drug adverse effects in 2008, which is 10,000 more compared to last year. PMDA attributed the increase to raised public awareness since October 2008 when over-the-counter drug makers started printing relief contact information on product packages. Since then monthly inquiries have jumped from 500-600 cases to 4,000 cases. Among the 962 cases seeking relief, the agency decided on 919 cases. It approved 784 cases and denied the rest. In 2009, the agency plans to carry out a survey targeting 3,300 physicians, dentists and nurses, and 3,000 citizens to further raise public awareness of the drug adverse effect relief system. (Click here for more - Japanese Language

You may also be interested in...

Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.

Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels

Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.

Endo Brings All Xiaflex Revenue In House With BioSpecifics Acquisition

Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts